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Insulin-like growth factors-1 and -2 (IGF-1 and IGF-2) are
polypeptide growth factors which play a crucial role in cell cycle
progression and cell proliferation as well as in cell differentiation
and cell death. They exert their mitogenic, cell transforming and
antiapoptotic signals by binding with high affinity to the IGF-1-
receptor (IGF-1R). The autocrine/paracrine and endocrine interac-
tion of IGFs with the IGF-1R is modulated by one of at least 6
insulin-like growth factor-binding proteins (IGFBPs). The IGFBPs
bind IGF-1 and IGF-2 with affinity constants that are between 2- and
50-fold greater than those for IGF-1R. In the blood, the principal
carrier of IGF-1 and IGF-2 is IGFBP-3. Because of its high affinity
constant, which is 10- to 20-fold greater than either IGFBP-1 or -2,
the other major forms of IGFBPs in the blood, IGFBP-3 binds
90–96% of IGF-1 and IGF-2 (Jones and Clemmons, 1995). 
Experimental and epidemiological evidence have suggested an
important role of the growth hormone (GH)-IGF-axis in the aeti-
ology and pathophysiology of colorectal tumours (Freier et al,
1999; Giovannucci, 1999). In this report, we present results from
the first study to investigate the associations between colorectal
cancer risk and concentrations of circulating IGF-1, IGF-2 and
IGFBP-3 in Chinese men using prospectively collected blood
samples. 
MATERIALS AND METHODS 
Subjects 
Subjects were drawn from a prospective study of men in Shanghai,
China (the Shanghai Cohort Study). Details of the cohort have
been previously published (Yuan et al, 1996). In brief, between
January 1, 1986 and September 30, 1989, all male residents of 4
small geographically defined communities in Shanghai, who were
aged 45–64 years and had no history of cancer, were invited to
participate in an epidemiological study. At enrolment, subjects
provided a 10 ml blood sample and a single void of urine. Samples
of serum were stored in both –70˚C and –20˚C freezers. Serum
samples used in the present study were those stored in -20˚C
freezers. Each subject was interviewed in person using a structured
questionnaire that included demographic information, history of
tobacco and alcohol use, current diet (45 items) and medical
history. A total of 18 244 men were enroled, constituting approxi-
mately 80% of eligible subjects. Follow-up has been conducted
by annual contacts with all surviving cohort members and
twice yearly review of cancer reports from the population-based
Shanghai Cancer Registry and of death certificates. By September
1998, 207 subjects had been lost to follow-up. Written informed
consent was obtained from all subjects in the study and the
described investigations were approved by both the University of
Southern California and the Shanghai Cancer Institute Institutional
Review Boards. 
Through follow-up ending September 1998, we identified
141 incident cases of colorectal cancer. For each case of incident
colorectal cancer, 5 controls were drawn with matching on
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year and month of sample collection. Statistical analysis was
restricted to subjects with complete measurements of all 3 IGF-
components. The sample size for this study, therefore, is 135 cases
and 661 control subjects, corresponding to 135 matched sets. The
median age at diagnosis among cases was 58 years. There were
66 colon cancer and 69 rectal cancer cases. 129 cases were
histopathologically confirmed. Among cases, the time interval
between recruitment and cancer diagnosis ranged from 3 months
to 12.3 years, with a mean of 6.1 years. 
Laboratory analysis 
Serum samples, including some quality control samples, were sent
to the laboratory of FZ Stanczyk for measurement of IGF-1, IGF-2
and IGFBP-3. Laboratory personnel were blinded to case–control
or quality control status of the samples. IGF-1 was quantified by
radioimmunoassay using commercial kits from Quest Diagnostics
at Nichols Institute (San Juan Capistrano, California). IGF-2 and
IGFBP-3 were measured by immunoradiometric assays with kits
obtained from Diagnostic Systems Laboratory (Webster, Texas).
Samples pertaining to matched subjects were assayed within a
single assay run (batch). 2 duplicate aliquots of quality control
samples were inserted in each of 24 batches to assess within-batch
variation. While IGF-2 and IGFBP-3 measurements were obtained
for all 48 quality control samples, IGF-1 values were only avail-
able for 45 quality control samples. The mean intra-batch coeffi-
cients of variation (standard deviation (SD)) for IGF-1, IGF-2 and
IGFBP-3 from the duplicate quality control samples were 5.4%
(SD 5.3), 3.2% (SD 4.0) and 6.5% (SD 6.8), respectively.
Complete IGF-1, IGF-2 and IGFBP-3 measurements were
performed on 135 case subjects and on 661 controls subjects,
respectively. 
Statistical analysis 
Data were analysed using SAS version 6.12 (Cary, NC). The
conditional logistic regression method was used to examine asso-
ciations between serum IGFs and risk of colorectal cancer
(Hosmer and Lemeshow, 1989). The magnitude of the associations
were measured by odds ratios (ORs) and their corresponding 95%
confidence intervals (Cls) and P values. All P values quoted are 2-
sided. Quintiles for IGF components were formed based on the
distributions of the measurements among control subjects. The
linear trend tests for exposure-disease associations were based on
continuous variables. In 5 of the 24 batches, one of the 2 duplicate
quality control samples demonstrated visibly larger variability
than the remaining 43 pairs of quality control samples with regard
to either IGF-1, IGF-2 or IGFBP-3 measurements. Statistical
analysis of data excluding either these 5 batches or the batch with
no IGF-1 quality control measurements did not materially alter the
findings of this study. All results presented are, therefore, based on
the total 135 cases and 661 control subjects. 
RESULTS 
Among control subjects, IGF-1, IGF-2 and IGFBP-3 were highly
correlated (IGF-1 vs. IGF-2: Spearman r = 0.51; IGF-2 vs. IGFBP-
3: r = 0.53; IGF-2 vs. IGFBP-3: r = 0.56; P ≤ 0.0001 for all r’s).
There were modest, but statistically significant correlations
between the IGF components and selected demographic factors,
specifically, between IGF-1 and age (r = –0.19,  P = 0.0001),
height (r = 0.12, P = 0.003), weight (r = 0.19, P = 0.0001), body
mass index (BMI; weight/height squared) (r = 0.16, P = 0.0001),
alcohol intake (g of ethanol per day) at baseline (r = 0.12, P =
0.003), and cigarette consumption (number of cigarettes smoked
per day) at baseline (r = –0.12, P = 0.002); between IGF-2 and age
(r = –0.11, P = 0.005), height (r = 0.11, P = 0.007), and weight (r =
0.09, P = 0.03); and between IGFBP-3 and height (r = 0.10, P =
0.01), weight (r = 0.16, P = 0.0001), and BMI (r = 0.12, P = 0.002). 
No statistically significant differences between case and control
subjects were reported with regard to anthropometric variables.
Mean height, weight and BMI for cases and controls were (168.6,
168.0 cm), (64.0, 63.0 kg), and (22.5, 22.3 kg m–2), respectively.
Alcohol and cigarette consumption were comparable between
cases and controls (weekly alcohol intake at baseline: 40% and
42%, respectively; daily cigarette consumption at baseline: 52%
vs 49%, respectively). 
Table 1 shows associations of IGF-1, IGF-2 and IGFBP-3 with
risk of colorectal cancer after adjustment for cigarette consump-
tion, alcohol intake and BMI. IGF-1 exhibited a statistically non-
significant positive association with colorectal cancer risk, which
disappeared after adjustment for IGFBP-3. For IGF-2, a 2.2-fold
elevated risk was observed for men in the highest versus the
lowest quintiles (P for trend = 0.03). The effect was diminished
after adjustment for IGFBP-3 (OR = 2.04, P for trend = 0.14).
Similarly, the positive association between IGFBP-3 and
colorectal cancer risk (P for trend = 0.07) was diminished when
adjustments were made for IGF-1 (OR = 1.78, P for trend = 0.13)
or IGF-2 (OR = 1.31, P for trend = 0.60). None of the 3 molar
ratios, IGF-1/IGFBP-3, IGF-2/IGFBP-3 and (IGF-1 + IGF-
2)/IGFBP-3, differed significantly between cases and controls
(Table 1). 
The potential modification of the observed associations by dura-
tion of follow-up was investigated (Table 2). Due to sample size
restrictions, quintiles for the IGF-components were collapsed
to form 2 levels only. Grouping of quintiles was based on quin-
tile/risk associations as presented in Table 1. There was no statisti-
cally significant association between IGF-1 and colorectal cancer
risk, irrespective of duration of follow-up. Both the IGF-2 and
IGFBP-3 associations with risk of colorectal cancer varied with
the duration of follow-up. For both IGF-2 and IGFBP-3, no asso-
ciation with colorectal cancer was observed beyond 8 years of
follow-up. IGF-2 showed a statistically significant association
with colorectal cancer within the first 8 years of follow-up (OR =
3.53 for the first 4 years of follow-up, and 2.41 for years 4–8 of
follow-up). These associations were slightly diminished after
adjustment for IGFBP-3, but remained statistically significant.
Similarly, IGFBP-3 was positively and statistically significantly
associated with colorectal cancer within the first 8 years of follow-
up (OR = 2.83 for the first 4 years of follow-up, and 2.85 for years
4–8 of follow-up). Adjustment for either IGF-1 or IGF-2 had only
minor effects on the positive IGFBP-3/colorectal cancer risk asso-
ciations. Irrespective of duration of follow-up no association
between cancer risk and the molar ratio (IGF-2/IGFBP-3) was
observed. 
No substantial modification of either the IGF-1 or the IGFBP-3
effect by cancer site was observed (data not shown). A strong
association was noted between rectal cancer and IGF-2 concentra-
tions within the first 4 years of follow-up without and with
IGFBP-3 adjustment. The ORs (95% Cls) were 7.00 (2.10–23.27)
and 6.51 (1.62–26.14), respectively. 
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Table 1 Odds ratios (OR)a of colorectal cancer according to quintiles of prediagnostic serum levels of IGF-1, IGF-2 and IGFBP-3 
Quintile P for trend 
1 (referent) 2 3 4 5
IGF-1 
No. case/controls 24/135 25/135 27/130 25/130 34/131
Mean, ng ml–1 100 135 159 188 246
OR 1.00 1.04 1.20 1.12 1.52 0.34 
95% Cl – 0.56–1.93 0.65–2.21 0.59–2.11 0.82–2.85
OR, IGFBP-3-adjustedb 1.00 0.97 1.05 0.96 1.18 0.96 
95% Cl – 0.51–1.82 0.55–2.01 0.48–1.91 0.55–2.53
IGF-2 
No. case/controls 22/136 22/133 21/132 31/129 39/131
Mean, ng ml–1 458 579 653 738 901
OR 1.00 1.05 1.03 1.61 2.20 0.03 
95% Cl – 0.55–2.01 0.53–2.00 0.86–3.02 1.15–4.20
OR, IGFBP-3-adjustedb 1.00 1.03 0.98 1.52 2.04 0.14 
95% Cl – 0.53–1.98 0.49–1.99 0.76–3.04 0.96–4.33
IGFBP-3 
No. case/controls 21/134 15/133 36/128 30/131 33/135
Mean, ng ml–1 1432 1824 2096 2385 3006
OR 1.00 0.73 1.93 1.58 1.72 0.07 
95% Cl – 0.36–1.49 1.05–3.53 0.84–2.98 0.91–3.25
OR, IGF-1 adjustedb 1.00 0.74 1.96 1.62 1.78 0.13 
95% Cl – 0.36–1.52 1.04–3.70 0.82–3.23 0.86–3.70
OR, IGF-2 adjustedb 1.00 0.67 1.68 1.29 1.31 0.60 
95% Cl – 0.33–1.39 0.87–3.22 0.62–2.67 0.59–2.91
Molar ratio (IGF-1/IGFBP-3) 
No. case/controls 28/130 27/132 25/133 27/134 28/132
Mean, ng ml–1 0.182 0.235 0.273 0.317 0.403
OR 1.00 0.93 0.86 0.91 0.96 0.52 
95% Cl – 0.51–1.68 0.46–1.59 0.49–1.72 0.48–1.89
Molar ratio (IGF-2/IGFBP-3) 
No. case/controls 25/133 29/131 27/132 31/130 23/135
Mean, ng ml–1 0.836 1.044 1.165 1.299 1.605
OR 1.00 1.16 1.09 1.23 0.81 0.37 
95% Cl – 0.63–2.12 0.58–2.03 0.65–2.31 0.38–1.72
Molar ratio (IGF-1 + IGF-2/IGFBP-3) 
No. case/controls 23/136 27/132 30/129 32/126 23/138
Mean, ng ml–1 1.069 1.303 1.443 1.594 1.947
OR 1.00 1.25 1.41 1.51 0.91 0.33 
95% Cl – 0.67–2.35 0.76–2.62 0.79–2.88 0.42–1.97
aall ORs are adjusted for cigarette smoking (number of cigarettes/day), alcohol intake (g ethanol/day), and body mass index (actual values) at baseline. 
bOR additionally adjusted for other IGF-components as stated. 
Table 2 Odds ratios (OR)a of colorectal cancer according to IGF-2 and IGFBP-3 levels, by duration of follow-up 
Duration of follow-up, years (mean) 
< 4 (2.3) 4–8 (6.0) ≥ 8 (9.9) 
Ca/Co OR (95% Cl) Ca/Co OR (95% Cl) Ca/Co OR (95% Cl) 
IGF-2 
1st–3rd quintiles 13/106 1.0 29/200 1.0 23/95 1.0 
4th–5th quintiles 21/59 3.53 (1.48–8.44)a 39/132 2.41 (1.31–4.41)a 10/69 0.61 (0.25–1.48)a 
2.92 (1.03–8.28)b 2.25 (1.16–4.37)b 0.66 (0.25–1.74)b 
IGFBP-3 
1st–2nd quintiles 8/75 1.0 15/140 1.0 13/52 1.0 
3th–5th quintiles 26/90 2.83 (1.18–6.79)a 53/192 2.85 (1.48–5.48)a 20/112 0.73 (0.31–1.71)a 
2.49 (0.96–6.43)c 3.20 (1.51–6.78)c 0.77 (0.30–1.95)c 
1.80 (0.67–4.85)d 2.56 (1.21–5.41)d 0.95 (0.36–2.49)d 
Molar Ratio (IGF-2/IGFBP-3) 
1st–3rd quintiles 20/91 1.0 38/199 1.0 23/106 1.0 
4th–5th quintiles 14/74 0.83 (0.34–2.07)a 30/133 1.32 (0.72–2.44)a 10/58 0.62 (0.22–1.74)a
aORs adjusted for body mass index (actual values), alcohol intake (g ethanol/day) and cigarette consumption (number of cigarettes/day) at baseline. 
bORs were additionally adjusted for IGFBP-3. 
cORs were additionally adjusted for IGF-1. 
dORS were additionally adjusted for IGF-2. DISCUSSION 
In the present study conducted in an Oriental population we found
that colorectal cancer cases had elevated circulating levels of IGF-
2 and IGFBP-3, which were evident only relatively shortly (i.e.,
within 8 years) before their clinical diagnosis of cancer. Previous
case–control and prospective studies involving mostly Caucasian
subjects have reported a rather consistent, though not always
statistically significant, positive association between circulating
IGF-1 levels and colorectal cancer. The epidemiological data are
equivocal with regard to the association of colorectal cancer and
endocrine IGFBP-3 or IGF-2 levels (El-Atiq et al, 1994; Ma et al,
1999; Manousos et al, 1999; Giovannucci et al, 2000; Kaaks et al,
2000). The confinement of the IGF-2 and IGFBP-3 effects to cases
diagnosed within 8 years of enrolment in our study is a novel
finding. 
The elevation in circulating IGF-components in the 8 years
preceding cancer diagnosis is unlikely to reflect behavourial
changes associated with early cancer symptoms, since acute
fasting as well as chronic caloric and protein restriction lead to
either no change or a decrease in circulating IGF-1, IGF-2 and
IGFBP-3 concentrations (El-Atiq et al, 1994; Thissen et al, 1994). 
Our results are compatible with a role of IGF-2 and IGFBP-3
elevations in the multistep process of colorectal carcinogenesis. In
vitro evidence indicates that IGF-2 stimulates growth of human
colorectal cancer and probably normal epithelial cells via an
autocrine pathway. Tumours which proliferate in response to
autocrine growth factors appear to grow more rapidly (Lamonerie
et al, 1995a). Neoplastic conversion of colonic cells is associated
with overexpression of IGF-2 gene and protein (Freier et al, 1999).
A high level of amplification and expression of the c-myc gene,
which is accompanied by an overexpression of IGF-2, differenti-
ates tumorigenic from non-tumorigenic clones of SW613-S human
colon carcinoma cell lines in a nude mice model. Proliferation of
the tumorigenic clones in vitro is dependent on the autocrine
production of IGF-2 (Lamonerie et al, 1995a, 1995b). The mecha-
nisms underlying the IGF-2 overexpression and the associated
increase in proliferation and tumorigenicity of colorectal cancer
cell lines are subject to ongoing research. Activating mutations
of the ras gene family and constitutive activation of pp60c-src,
the product of the src proto-oncogene, are among the genetic
and epigenetic alterations most frequently observed in human
colorectal cancer. In CaCo-2 cell lines which exhibit these
frequent alterations, the 2 oncogenes deregulate the proliferation
of human colonic cells by stimulating IGF-II production through a
protein kinase C pathway. This pathway presumably stimulates
interaction of the transcription factor Sp1 with several specific
binding sites in P3 and P4 promoters of the IGF-2 gene (Cadoret
et al, 1998). Studies of CaCo-2 colon carcinoma cell lines sug-
gest that IGF-2 overexpression then impacts on cell proliferation
by up-regulating the expression of cyclo-oxygenase-2 and
prostaglandin E2 (Popolo et al, 2000). 
The in vitro results are compatible with results from animal
studies. Genetic manipulation to increase IGF-2 expression in the
intestinal tract of 24 ApcMin/+ mice, a murine model of human
familial adenomatous polyposis, increased the number and diam-
eter of colon adenomas and the likelihood of histological progres-
sion to carcinoma in comparison to 17 ApcMin/+ mice with
normal IGF-2 expression (Hassan and Howell, 2000). Growth
hormone-releasing hormone (GH-RH) antagonists were found to
inhibit growth of human HT-29 colon cancer cells transplanted
into male nude mice. The treatment, which was started between 7
and 19 days after the transplantation of colon cancer cells, signifi-
cantly decreased protein and expression levels of IGF-2 in the
developing cancers when compared to control mice not treated
with GH-RH antagonists (Szepeshazi et al, 2000). 
Thus, experimental evidence is compatible with a central role of
IGF-2 in neoplastic transformation and progression of colon
epithelial cells. Interestingly, this possible aetiologic role of IGF-2
may be reflected in its peripheral blood levels. Among volunteers
aged 55–64 undergoing flexible sigmoidoscopy, IGF-2 protein
was overexpressed in adenomatous but not hyperplastic polyps.
Circulating IGF-2 levels, which also were high in subjects with
adenomatous polyps, dropped to normal levels after polyp
removal (Renehan et al, 2000). Circulating IGF-2 levels, thus, may
serve as a risk marker in individuals with colorectal adenomas, a
hypothesis that is compatible with our study results. A role of IGF-
2 in cancer susceptibility is also suggested by loss of imprinting
(LOI) of the IGF-2 gene in both tumour tissue and matched normal
colonic mucosa of 44% of colorectal cancer patients (Cui et al,
1998). 
There is limited laboratory evidence in support of a positive
association between IGFBP-3 and colorectal tumour progression.
Experiments with colon cancer cell lines indicate that IGFBP-3,
bound to cell surfaces or to the extracellular matrix, potentiates
IGF-1 action by enhancing its interaction with the IGF-1R (Jones
and Clemmons, 1995; Ferry et al, 1999). Upon exposure to trans-
forming growth factor (TGF) beta 1, many human colon carci-
noma cells undergo proliferation and exhibit a highly metastatic
phenotype. In vitro results suggest that the proliferative TGF beta
1 effect may be mediated through the induction of IGFBP-3
(Kansra et al, 2000). The relevance of circulating IGFBP-3 on the
biological activity of IGFs is unresolved. It has been suggested
that bioavailable circulating IGF-1 concentrations are regulated by
IGFBP-1 and IGFBP-2 rather than IGFBP-3, despite the higher
peripheral concentrations of IGFBP-3 (Kaaks et al, 2000). A small
case–control study found elevated circulating concentrations of
both, IGFBP-2 and IGFBP-3, among patients with colorectal
cancer (El-Atiq et al, 1994). Mutations in IGFBP-3 have been
found in colorectal cancers, although the functional significance of
such mutations is not known (Zou et al, 1998). 
In conclusion, among Chinese men in Shanghai, circulating
IGF-2 and IGFBP-3 levels were elevated in colorectal cancer
cases up to 8 years before the clinical diagnosis of cancer. These
results are potentially relevant for colorectal cancer screening and
colorectal adenoma surveillance. 
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